Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic (NYSE:MDT) agreed to acquire Scientia Vascular for $550 million, subject to customary adjustments and potential earn‑outs, to integrate Scientia's guidewires and catheters into Medtronic's neurovascular portfolio.
The deal covers ~310 employees, targets faster access in stroke care, is expected to close in 1H FY27, and is forecast to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter.
MiniMed Group (Nasdaq: MMED) began trading March 6, 2026 on the Nasdaq Global Select Market following an oversubscribed IPO.
The offering was described as the second largest IPO in medtech history and positions MiniMed to operate as a standalone company, while supporting Medtronic (NYSE: MDT)'s capital-focus strategy amid geopolitical market uncertainty.
MiniMed Group (planned Nasdaq: MMED) priced an initial public offering of 28,000,000 shares at $20.00 per share, with expected Nasdaq trading to begin March 6, 2026 and closing of the offering expected March 9, 2026, subject to customary conditions.
MiniMed granted underwriters a 30-day option for up to 4,200,000 additional shares. Upon completion, Medtronic is expected to retain approximately 90.03% ownership (88.70% if the over-allotment is fully exercised). Proceeds will fund general corporate purposes and may repay intercompany debt to Medtronic.
Medtronic (NYSE: MDT) announced a cash dividend of $0.71 per ordinary share for the fourth quarter of fiscal 2026. The board approved the dividend on March 5, 2026, payable April 17, 2026, to shareholders of record at the close of business on March 27, 2026.
Medtronic noted this quarterly declaration aligns with its May 2025 dividend increase and highlighted its 48-year streak of consecutive annual dividend increases as a member of the S&P 500 Dividend Aristocrats.
Medtronic (NYSE:MDT) announced that Thierry Piéton, executive vice president and chief financial officer, will appear in fireside chats at two investor conferences on March 10–11, 2026.
Live webcasts will be available via the company's investor events page, with archived recordings posted later the same day.
Medtronic (NYSE: MDT) launched the MiniMed Go™ Smart MDI system with the Simplera™ sensor across Europe beginning Feb 2026. The system integrates InPen™ smart insulin pen and Simplera™ CGM into one app, offering real-time dose calculation, missed-dose alerts, CareLink Clinic MDI reports, and expanded pediatric labeling.
Rollout is gradual across Europe; Instinct Go™ compatibility is pending CE mark and Simplera™ compatibility in the U.S. is under FDA review.
MiniMed Group (proposed Nasdaq: MMED) launched its IPO roadshow on Feb 24, 2026, offering 28,000,000 shares with an expected price range of $25.00–$28.00 per share and a 30-day over-allotment option for 4,200,000 shares.
Upon completion Medtronic (NYSE: MDT) would retain approximately 90.03% ownership (or 88.70% if the over-allotment is exercised). Proceeds will fund general corporate purposes, repay intercompany debt, and provide additional consideration to Medtronic. A Form S-1 has been filed but is not yet effective.
Medtronic (NYSE: MDT) reported Q3 FY26 revenue of $9.017 billion, up 8.7% as reported and 6.0% organic, with GAAP diluted EPS of $0.89 and non-GAAP diluted EPS of $1.36.
Notable drivers: Cardiac Ablation Solutions +80% (U.S. +137%), Diabetes organic +8.3%, CE Mark for Sphere-360, U.S. FDA clearances for Hugo robotic surgery and Stealth AXiS, and two M&A deals (CathWorks, Anteris). Company reiterated FY26 organic revenue ~5.5% and non-GAAP EPS guidance of $5.62–$5.66 (tariff impact ~$185M).
Medtronic (NYSE:MDT) announced that the first U.S. commercial surgical case using the FDA-cleared Hugo™ robotic-assisted surgery (RAS) system was performed at Cleveland Clinic on Feb. 17, 2026, where a robotic-assisted prostatectomy was completed and the patient discharged the next day.
The Hugo RAS system completed the Expand URO IDE study meeting primary safety and effectiveness endpoints and is available in more than 35 countries; Medtronic plans indication expansion into gynecologic and general surgery.
Medtronic (NYSE: MDT) announced FDA clearance of the Stealth AXiS™ surgical system on Feb 13, 2026, a unified platform that integrates planning, navigation and robotics for spine surgery.
The system features LiveAlign™ segmental tracking for real-time anatomic motion visualization, a modular robotic design for staged deployment, and architecture intended to support future cranial and ENT applications pending 510(k) clearance.